Savvy Updates 6/8/22: More on Dexcom, CGM Accuracy Study, CGM Alarm Fatigue, Prior Authorizations Reform (NOT)
More on Dexcom: Dexcom CEO Sayer on G7 FDA submission, developing a 15-day sensor, M&A plans was published by Ricky Zipp for MedTechDive.com, 7 June 2022. The executive spoke about the company’s discussions with the FDA on the G7 CGM system,...
Savvy Updates, 6/6/22: Abbott Libre 3 & Lingo, Diabeloop $$, iLet Bionic Pancreas Trial, Apple Watch BG Monitoring, Medtronic Struggles, Diabetes & Long Covid, Dexcom Denies Rumors, Pharmacy Benefit Managers Cost Consumers
ABBOTT NEWS US FDA approves Abbott’s FreeStyle Libre 3 system for diabetic patients was reported by MedicalDevice-Network.com, 1 June 2022. The US Food and Drug Administration (FDA) has granted clearance to Abbott’s next-generation FreeStyle...
Savvy Updates 5/30/22: Dexcom-Insulet Purchase Discussion, Medtronic’s Continuing Supply Chain Woes, Levicure Ltd Aims for Oral Treatment for T1D
How a Dexcom-Insulet combination would shake up the diabetes treatment industry was published by Ricky Zipp for MedTechDive.com, 25 May 2022. After last year’s barrage of deal-making in the medical device industry, there have been few acquisitions in...
Open Letter to the US FDA from The Savvy Diabetic re FDA, Interoperability Mandate and End-User On-Device, Continuous Access to OUR OWN CGM DATA
OPEN LETTER to: • Robert M. Califf, M.D., Commissioner of Food & Drugs, USFDA • Jeffrey E. Shuren, M.D., J.D. Director, Ctr for Devices & Radiological Health, US FDA • Kellie Kelm, Ph.D, Director, Office of Health Technology 7, US FDA • Yiduo Wu, Ph.D., Branch...
More Diabetes Blogs